![](/img/cover-not-exists.png)
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
Freiburghaus, Catja, Emruli, Venera Kuci, Johansson, Angelica, Eskelund, Christian Winther, Grønbæk, Kirsten, Olsson, Roger, Ek, Fredrik, Jerkeman, Mats, Ek, SaraVolume:
18
Language:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-018-4346-1
Date:
December, 2018
File:
PDF, 5.02 MB
english, 2018